-
公开(公告)号：EP1080068A1
公开(公告)日：2001-03-07
申请号：EP99907336.4
申请日：1999-03-12
发明人： RICHTER, Lutz Stefan , ANDERSEN, Henrik Sune , VAGNER, Josef , JEPPESEN, Claus, Becker , MOELLER, Niels P H , BRANNER, Sven , JEPPESEN, Lone , OLSEN, Ole Hvilsted , IVERSEN, Lars Fogh , HOLSWORTH, Daniel Dale , AXE, Frank Urban , GE, Yu , JONES, Todd, Kevin , RIPKA, William Charles , UYEDA, Roy Teruyuki , SU, Jing , BAKIR, Farid , JUDGE, Luke Milburn
IPC分类号： C07C235/84
CPC分类号： C07D213/79 , C07C233/56 , C07C237/22 , C07D207/34 , C07D209/08 , C07D209/14 , C07D213/80 , C07D231/40 , C07D239/42 , C07D239/557 , C07D241/26 , C07D261/08 , C07D271/07 , C07D271/10 , C07D271/113 , C07D333/38 , C07D333/66 , C07D333/68 , C07D409/04 , C07D409/06 , C07D413/04 , C07D495/04 , C07D495/10 , C07D495/14
摘要： The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPν, PTPδ, PTPσ, PTPz, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes.
-
公开(公告)号：EP2681237A1
公开(公告)日：2014-01-08
申请号：EP12707996.0
申请日：2012-03-01
申请人： Novo Nordisk A/S
发明人： ANDERSEN, Mette Dahl , NOERDBY, Peder Lisby , KJAERGAARD, Kristian , GRELL, Susanne Nedergaard , GRUHLER, Albrecht , BUCHARDT, Jens , ANDERSEN, Henrik Sune , PADKJAER, Soeren , KASTRUP, Jesper , HAAKANSSON, Katarina , HORNUM, Lars , FRIEDRICHSEN, Birgitte , BAUNSGAARD, Dorrit
IPC分类号： C07K14/705 , C07K16/28 , A61K39/395 , A61P37/00
CPC分类号： A61K47/6803 , A61K47/545 , A61K2039/505 , C07K14/70578 , C07K16/2863 , C07K16/2878 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
摘要： The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
摘要翻译： 本公开涉及炎性疾病的治疗。 特别地，本发明涉及可用于治疗炎性疾病的拮抗性DR3配体。
-
3.发明公开COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT 审中-公开复合制剂什么A 11-β-羟基 - 脱氢酶TYPE 3抑制剂和抗高血压剂CONTAIN
公开(公告)号：EP1615666A2
公开(公告)日：2006-01-18
申请号：EP04725887.6
申请日：2004-04-06
申请人： NOVO NORDISK A/S
摘要： Combination therapy comprising the administration of an 11ß-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
-
-
搜索结果
3 条记录 (耗时 0.018 秒)
